Back to News
Market Impact: 0.2
Equillium Doses First Subject In Phase 1 Study Of Oral Inflammation Drug Candidate EQ504
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Equillium dosed the first subject in Australia in its Phase 1 clinical trial of EQ504, an investigational oral, colon-targeted AhR modulator for serious inflammatory diseases. The announcement marks the start of dosing but provides no trial results or additional efficacy data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
EQ0.45
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios
- Labubu-maker Pop Mart's shares extend declines as third-quarter sales plunge